AK129 Combination Therapy for Advanced Solid Tumors
A phase 1/2 trial of Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
Overview
AK129 Combination Therapy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06943820 by Akeso, with 230 participants planned, started 2025-05-21 and due to reach its primary completion in 2026-12. Interventions recorded: AK129(dose 1), Pemetrexed, Paclitaxel, Carboplatin, AK129(dose 2). Conditions listed: Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Akeso, Docetaxel, Pemetrexed, Paclitaxel / nab-paclitaxel.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Shares Docetaxel, Pemetrexed, Carboplatin, Small-cell lung cancer.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Akeso, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Paclitaxel / nab-paclitaxel, Carboplatin, Head and neck squamous cell carcinoma.
- TrialVolrustomig Priming Regimens Exploratory Phase II Platform Study
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.